• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aptose Bioscns (NQ: APTO )

    0.7300 +0.0199 (+2.80%)
    Streaming Delayed Price Updated: 10:30 AM EDT, Jul 10, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Aptose Bioscns

    < Previous 1 2 3 4 5 Next >
    Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving Premarket
    Gainers 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Thursday
      Thursday saw 177 companies set new 52-week lows. 
    Via Benzinga
    Aptose Biosciences: Q2 Earnings Insights
    Aptose Biosciences (NASDAQ:APTO) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Aptose Biosciences Establishes New At-The-Market Facility
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
    Data to be presented in poster at ASH Annual Meeting 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
    Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60. 
    Via Benzinga
    Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
    Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry. 
    Via Benzinga
    Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting
    Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose Reports Results for the Third Quarter 2022
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Stocks That Hit 52-Week Lows On Tuesday
      On Tuesday, 120 companies set new 52-week lows. 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
      During Tuesday's session, 78 companies made new 52-week lows. 
    Via Benzinga
    The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
    Here's a roundup of top developments in the biotech space over the last 24 hours. 
    Via Benzinga
    FDA Grants Fast Track designation To Aptose Biosciences for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation
    Aptose Biosciences Inc. (NASDAQ: APTO) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of... 
    Via Benzinga
    38 Stocks Moving In Wednesday's Mid-Day Session
    Gainers Allego N.V. (NYSE: ALLG) shares jumped 158.5% to $21.41 after the company announced the completion of its merger agreement with Spartan Acquisition Corp., which resulted... 
    Via Benzinga
    The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
    Here's a roundup of top developments in the biotech space over the last 24 hours. 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Rise and shine, trader! We're starting off the day with a breakdown of the biggest pre-market stock movers for Wednesday! 
    Via InvestorPlace
    32 Stocks Moving in Wednesday's Pre-Market Session
    Gainers Zentek Ltd. (NASDAQ: ZTEK) rose 180.5% to $7.63 in pre-market trading after declining around 5% on Tuesday. Creative Realities Inc (NASDAQ: CREX) shares rose 52.6% to $1.... 
    Via Benzinga
    Aptose Biosciences: Q4 Earnings Insights
    Aptose Biosciences (NASDAQ:APTO) reported its Q4 earnings results on Tuesday, March 22, 2022 at 04:01 PM. Here's what investors need to know about the announcement.... 
    Via Benzinga
    The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Earnings Scheduled For March 22, 2022
    Companies Reporting Before The Bell • GDS Holdings (NASDAQ:GDS) is projected to report quarterly loss at $0.18 per share on revenue of $338.69 million. • HUYA (... 
    Via Benzinga
    Earnings Preview: Aptose Biosciences
    Aptose Biosciences (NASDAQ:APTO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-22. Here's what investors need to know before the announcement. Analysts... 
    Via Benzinga
    Earnings Outlook For Aptose Biosciences
    Aptose Biosciences (NASDAQ:APTO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-22. Here's what investors need to know before the announcement. Analysts... 
    Via Benzinga
    Earnings Preview For Aptose Biosciences
    Aptose Biosciences (NASDAQ:APTO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-22. Here's what investors need to know before the announcement. Analysts... 
    Via Benzinga
    The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
    Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Good morning! In preparation for another busy day of trading, we've put together a list of the biggest pre-market stock movers for Thursday! 
    Via InvestorPlace
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.